Regorafenib is considered a potential therapeutic agent for CCA as several molecular alterations [42], particularly disruption of the MAPK pathway and activation of Ras and BRAF by mutations, have been described in CCA [43–45]. The gene discussed is BRAF; the disease is cholangiocarcinoma.